Moderna stock continued to rise in premarket trading in the United States on Friday after the firm indicated a new vaccine to combat the omicron form of the coronavirus might be ready by early 2022 if needed.

After surging 21% during Friday's selloff, the stock recovered 9.9%, resuming its position as the S&P 500's best performer year-to-date. According to Chief Medical Officer Paul Burton, the business dispatched hundreds of workers on Thanksgiving Day last Thursday to begin work on omicron. Moderna is currently up 10% premarket.

Severe and Asymptomatic Data Could Give Moderna's COVID-19 Vaccine Slight Edge Over Pfizer's :: Pink Sheet

According to Piper Sandler analyst Edward A. Tenthoff, who has an overweight rating on the company, Moderna's mRNA technology is perfect for adjusting vaccinations to novel variations.

In a note to clients, Tenthoff said, "Moderna is in a stronger position to create novel Covid-19 vaccines, and now has the capacity to manufacture several hundred million vaccine doses every month." "SARS-CoV-2 is here to stay and will generate money for years to come."

Moderna investors should be encouraged by the current spread, according to Jefferies analyst Michael Yee, who believes that the biotech's focus on a new version for 2022 could motivate individuals to get boosted sooner rather than later. Moderna claims to be able to "promote novel candidates to clinical trials in 60-90 days."

BioNTech SE increased by 4.7 % after announcing that it is adapting its Covid-19 vaccine to address the omicron strain and expects to have a new formulation ready within 100 days if necessary. Months ago, the biotech and its Covid vaccination partner, Pfizer, devised a strategy. At 6:53 A.M. in New York, Pfizer stock was up 1.2 %.

Novavax. and Adagio Therapeutics, two firms exploring vaccinations and medicines to battle Covid, also saw their stock rise. Premarket, Novavax rose 4.3 % as B Riley analysts emphasized the importance of booster doses, while Adagio surged 17 % on plans to submit its antibody for emergency usage in mid-2022.